^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

eseba-vec (HB-200)

i
Other names: HB-200, HB200, HB-202/HB-201, alternating 2-vector HB-202/HB-201, HB-202/HB-201 alternating
Company:
Hookipa Pharma
Drug class:
HPV-16 E6 protein inhibitor, HPV-16 E7 protein inhibitor
4ms
New P2/3 trial • Metastases
|
Keytruda (pembrolizumab) • eseba-vec (HB-200) • HB-201
4ms
Phase II multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy of HB-200 in patients with detectable TTMV-HPV DNA after definitive treatment for HPV16 + HNSCC (ESMO 2024)
The primary objective is to assess the disease-free survival (DFS) for pts enrolled in the study receiving either HB-200 or placebo. The secondary objectives include overall survival, and safety.
P2 data • Clinical
|
NavDx®
|
eseba-vec (HB-200)
7ms
A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers (clinicaltrials.gov)
P1/2, N=200, Recruiting, Hookipa Biotech GmbH | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Mar 2024 --> Jun 2025
Trial completion date • Trial primary completion date • Metastases
|
Keytruda (pembrolizumab) • eseba-vec (HB-200) • HB-201
7ms
Naveris Announces Launch of Phase II Clinical Study in MRD+ Head and Neck Cancer (Businesswire)
"Naveris, Inc...announced the launch of a Phase II clinical study in minimal residual disease positive (MRD+) HPV-driven head and neck cancer. The study will be led by Memorial Sloan Kettering Cancer Center (MSKCC), a top cancer treatment and research institution. The primary objective of this multicenter randomized study is to evaluate the efficacy of HB-200, a novel intervention, for patients with HPV16+ head and neck squamous cell cancer (HNSCC) with molecular relapse, defined as the presence of circulating Tumor Tissue Modified Viral (TTMV)-HPV DNA without clinical or radiographic evidence of recurrence following definitive treatment."
Trial status
|
NavDx®
|
eseba-vec (HB-200)
7ms
New P2 trial
|
eseba-vec (HB-200) • HB-201
11ms
Trial completion date • Trial primary completion date • Metastases
|
Keytruda (pembrolizumab) • eseba-vec (HB-200) • HB-201
1year
Characterization of tumor specific CD8+ T cell responses in patients with recurrent/metastatic HPV16-positive head and neck cancer receiving HB-200 monotherapy as second or later line treatment in a phase 1 study (SITC 2023)
HB-200 is comprised of an alternating sequence of two replicating attenuated arenavirus vectors derived from LCMV (HB-201) and Pichinde virus (HB-202), respectively, expressing the same non-oncogenic HPV16 E7E6 fusion protein. Conclusions HB-200 monotherapy induces promising HPV16+ tumor-specific T cell responses and tumor infiltration in heavily pre-treated patients. This immune response coupled with clinical benefit in monotherapy suggests that HB-200 may enhance and strengthen current immunotherapy approaches by targeting specific tumor antigens.
Clinical • P1 data • Metastases
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma)
|
eseba-vec (HB-200) • HB-201
over1year
HB-200 arenavirus-based immunotherapy plus pembrolizumab as a first-line treatment of patients with recurrent/metastatic HPV16 positive head and neck cancer (ESMO 2023)
HB-200 is comprised of an alternating sequence of two replicating attenuated arenavirus vectors derived from LCMV (HB-201) and Pichinde virus (HB-202), respectively. Conclusions Preliminary data with HB-200 arenavirus-based immunotherapy plus pembrolizumab demonstrate a favorable safety profile and preliminary efficacy when given as a 1L treatment of patients with R/M HPV16+ PD-L1+ HNSCC. Clinical trial# NCT04180215.
Clinical • Metastases
|
CD8 (cluster of differentiation 8)
|
Keytruda (pembrolizumab) • eseba-vec (HB-200)
over1year
A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers (clinicaltrials.gov)
P1/2, N=200, Recruiting, Hookipa Biotech GmbH | Trial primary completion date: Jun 2023 --> Mar 2024
Trial primary completion date • Metastases
|
Keytruda (pembrolizumab) • eseba-vec (HB-200) • HB-201
over2years
HB-201 and HB-202, an arenavirus-based immunotherapy, induces tumor T cell infiltration in patients with HNSCC and other HPV16+ tumors (AACR 2022)
In this updated dataset, we show that HB-201 and HB-202/HB-201, rapidly induce unprecedented E6/E7 specific T cell levels in circulation following a single dose. Furthermore, these data are seen in conjunction with a pronounced increase of post-treatment CD8+ T cells in tumor, suggesting E6/E7 specific T cell infiltration. Our arenavirus vectors expressing the E7E6 fusion antigen demonstrate an attractive and safe therapy for patients with treatment refractory HPV16+ cancers.
Clinical
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma)
|
eseba-vec (HB-200) • HB-201
3years
Development and Characterization of a Novel Non-Lytic Cancer Immunotherapy Using a Recombinant Arenavirus Vector Platform. (PubMed, Front Oncol)
This response can be further enhanced by alternating injections of HB-202 and HB-201, which has resulted in frequencies of circulating HPV16 E7/E6-specific CD8 T cells of up to 40% of the total CD8 T cell compartment in peripheral blood in analyses to date. Treatment with intravenous administration also resulted in a disease control rate of 73% among 11 evaluable patients with head and neck cancer dosed every three weeks, including 2 patients with a partial response.
Review • Journal
|
CD8 (cluster of differentiation 8)
|
eseba-vec (HB-200) • HB-201
over3years
[VIRTUAL] Preliminary immunogenicity analysis of HB-201 and HB-202, an arenavirus-based cancer immunotherapy, in patients with advanced HPV16+ cancers (CIMT 2021)
These preliminary data provide the first demonstration of arenavirus vectors ability to induce HPV16-specific T cells in cancer patients. This is achieved following a single injection of HB-201 or HB-202. Arenavirus vectors expressing E7E6 may constitute a new potential therapy for patients with treatment refractory HPV16+ cancers.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma)
|
eseba-vec (HB-200) • HB-201